The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.

The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.

Meanwhile, Tango tries again in PRMT5.

The company abandons TNG908, but is still all in on the troubled target.

Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.

New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.

Initial data on Amgen’s AMG 193 give some Tango investors a headache.

But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.